AstraZeneca T\u00fcrkiye Ruhsatland\u0131rma ve Pazar Eri\u015fim Direkt\u00f6r\u00fc<\/strong><\/p>\n\n\n\n Sizi biraz tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n 2003 y\u0131l\u0131nda Bilkent \u00dcniversitesi End\u00fcstri M\u00fchendisli\u011fi B\u00f6l\u00fcm\u00fc\u2019nden mezun olduktan sonra 2005 y\u0131l\u0131nda Amerika\u2019da Pittsburgh \u00dcniversitesi\u2019nde End\u00fcstri M\u00fchendisli\u011fi B\u00f6l\u00fcm\u00fc\u2019nde y\u00fcksek lisans\u0131m\u0131, 2010 y\u0131l\u0131nda ise t\u0131pta karar alma konusunda doktoram\u0131 tamamlad\u0131m. Kariyerime 2003 y\u0131l\u0131nda ABD\u2019de Pittsburgh \u00dcniversitesi\u2019nde ara\u015ft\u0131rma g\u00f6revlisi olarak ba\u015flad\u0131m. 2008 – 2009 y\u0131llar\u0131 aras\u0131nda yine ABD\u2019de Merck & CO\u2019da global sa\u011fl\u0131k ekonomisti olarak g\u00f6rev ald\u0131m. Daha sonra T\u00fcrkiye\u2019ye d\u00f6nerek s\u0131ras\u0131yla 2010-2011 y\u0131llar\u0131 aras\u0131nda Bayer\u2019de sa\u011fl\u0131k ekonomisi ve sonu\u00e7 ara\u015ft\u0131rmalar\u0131 m\u00fcd\u00fcr\u00fc, 2012-2013 y\u0131llar\u0131 aras\u0131nda Merck Sharp & Dohme\u2019de pazar eri\u015fim direkt\u00f6r yard\u0131mc\u0131s\u0131, 2014-2016 y\u0131llar\u0131 aras\u0131nda Amgen\u2019da k\u0131demli pazar eri\u015fim m\u00fcd\u00fcr\u00fc, 2016 \u2013 2020 tarihleri aras\u0131nda AbbVie\u2019de Ppazar eri\u015fim ve resmi ili\u015fkiler direkt\u00f6r\u00fc olarak \u00e7al\u0131\u015ft\u0131m. 2020 y\u0131l\u0131ndan bu yana ise AstraZeneca T\u00fcrkiye\u2019de ruhsatland\u0131rma ve pazar eri\u015fim direkt\u00f6r\u00fc olarak g\u00f6rev yap\u0131yorum.<\/p>\n\n\n\n Pazar eri\u015fim birimleri ila\u00e7 sekt\u00f6r\u00fcnde nas\u0131l bir ihtiya\u00e7la kuruldu ve nas\u0131l geli\u015fti?<\/strong><\/p>\n\n\n\n Pazar eri\u015fim birimleri, hastalar\u0131n en do\u011fru tedavilere ula\u015fmas\u0131n\u0131 desteklemeyi ama\u00e7l\u0131yor.<\/p>\n\n\n\n Fiyatland\u0131rma, geri \u00f6deme, sa\u011fl\u0131k ekonomisi gibi ila\u00e7 sekt\u00f6r\u00fcne \u00f6zg\u00fc s\u00fcre\u00e7lerin y\u00fcr\u00fct\u00fclmesini ve yenilik\u00e7i tedavilerin d\u00fcnya genelinde maksimum say\u0131da ihtiya\u00e7 sahibi ki\u015fiye ula\u015fmas\u0131n\u0131 sa\u011fl\u0131yor. Bu birim d\u00fcnyada ve \u00fclkemizde son y\u0131llarda \u00f6nemi giderek artan, stratejik ve temel bir fonksiyon olma \u00f6zelli\u011fi ta\u015f\u0131yor. Pazar eri\u015fimin \u00f6nemi \u015firketlerin sadece \u00fclke organizasyonlar\u0131nda de\u011fil, b\u00f6lge ve global organizasyonlar\u0131nda da y\u00fckseli\u015fte, ayr\u0131ca \u00fcst y\u00f6netim ekiplerinde de temsil ediliyor. Ruhsatland\u0131rma ve pazar eri\u015fim AstraZeneca T\u00fcrkiye\u2019de de i\u015f birimleri, finans, medikal, kurumsal ili\u015fkiler, insan kaynaklar\u0131 ve sat\u0131\u015f kanallar\u0131 ile \u00fclke y\u00f6netim kurulunda temsil edilen kilit \u00f6neme sahip bir fonksiyon.<\/p>\n\n\n\n \u0130la\u00e7lar\u0131n pazara eri\u015fim s\u00fcre\u00e7leri a\u00e7\u0131s\u0131ndan T\u00fcrkiye\u2019deki genel durumu d\u00fcnya ile k\u0131yaslad\u0131\u011f\u0131n\u0131zda neler s\u00f6ylemek istersiniz?<\/strong><\/p>\n\n\n\n T\u00fcrkiye sa\u011fl\u0131k ve ila\u00e7 end\u00fcstrisi a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck bir potansiyele sahip. Ba\u015fta \u0130stanbul ve Ankara olmak \u00fczere \u00f6zel, kamu ve \u00fcniversite hastaneleri d\u00fcnyadaki en y\u00fcksek teknolojilerle donat\u0131lm\u0131\u015f durumda. Mevcut ila\u00e7lara ve sa\u011fl\u0131k hizmetlerine eri\u015fim sa\u011flan\u0131yor olsa da yeni ila\u00e7lara eri\u015fimi kolayla\u015ft\u0131racak s\u00fcre\u00e7lerin iyile\u015ftirilmesine duyulan gereksinim devam ediyor. Avrupa\u2019da 2018-2021 y\u0131llar\u0131 aras\u0131nda hastalara sunulan yeni ila\u00e7lar\u0131n say\u0131s\u0131 168 iken T\u00fcrkiye\u2019de bu say\u0131 10 oldu. Avrupa \u0130la\u00e7 \u00dcreticileri ve Birlikleri Federasyonu\u2019nun (EFPIA) 2023\u2019te yay\u0131mlad\u0131\u011f\u0131 Hastalar\u0131n Yenilik\u00e7i Tedavilere Eri\u015fimi Bekleme Raporu\u2019na g\u00f6re, 2018- 2021 y\u0131llar\u0131 aras\u0131nda Avrupa \u00fclkelerinin yeni ruhsat alan ila\u00e7lara eri\u015fimine bak\u0131ld\u0131\u011f\u0131nda, T\u00fcrkiye\u2019deki hastalar, belirtilen son d\u00f6rt y\u0131lda Avrupa Birli\u011fi\u2019nde onay alm\u0131\u015f yeni ila\u00e7lar\u0131n y\u00fczde 94\u2019\u00fcne eri\u015femiyor. Ayn\u0131 raporda son d\u00f6rt y\u0131lda yeni ila\u00e7lar\u0131n sadece y\u00fczde 21\u2019inin T\u00fcrkiye\u2019ye geldi\u011fi g\u00f6r\u00fcl\u00fcyor. <\/p>\n\n\n\n 2015 – 2021 y\u0131llar\u0131 aras\u0131nda ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA) taraf\u0131ndan onaylanan 300 ilac\u0131n yaln\u0131zca 44\u2019\u00fc T\u00fcrkiye\u2019de ruhsat ald\u0131. \u00dclkemizin dahil oldu\u011fu referans fiyat sistemi do\u011frultusunda sekt\u00f6r\u00fcm\u00fcz\u00fcn s\u00fcreklili\u011fi ve s\u00fcrd\u00fcr\u00fclebilirli\u011fi a\u00e7\u0131s\u0131ndan iyile\u015ftirmeye ihtiya\u00e7 duyuluyor. Bu konuda gerek kamu gerek \u00f6zel sekt\u00f6r gerekse akademik \u00e7evreler ile her zaman i\u015f birlikleri yapmaya, \u00fczerimize d\u00fc\u015fen t\u00fcm sorumlulu\u011fu yerine getirmeye haz\u0131r oldu\u011fumuzu bu vesileyle bir kez daha vurgulamak isterim.<\/p>\n\n\n\n Pazar eri\u015fim ve ruhsatland\u0131rma biriminin \u015firket organizasyonunuz i\u00e7indeki yerinden ve faaliyet alan\u0131ndan bahseder misiniz? En \u00f6nemli payda\u015flar\u0131n\u0131z kimler?<\/strong><\/p>\n\n\n AstraZeneca T\u00fcrkiye Ruhsat ve Pazar Eri\u015fim Direkt\u00f6rl\u00fc\u011f\u00fc b\u00fcnyesinde ruhsatland\u0131rma, fiyatland\u0131rma, geri \u00f6deme, stratejik sa\u011fl\u0131k inisiyatifleri ve sa\u011fl\u0131k politikalar\u0131 fonksiyonlar\u0131 yer al\u0131yor. \u015eirketimizin ara\u015ft\u0131rma ve geli\u015ftirme hatt\u0131nda bulunan, klinik \u00e7al\u0131\u015fmalar\u0131 devam eden ya da farkl\u0131 \u00fclkelerde sa\u011fl\u0131\u011f\u0131n hizmetine sunulmu\u015f olan fakat T\u00fcrkiye\u2019de hen\u00fcz hastalara eri\u015fimi bulunmayan \u00fcr\u00fcnlerimiz i\u00e7in ise \u00fclkemize ve \u00fcr\u00fcne \u00f6zg\u00fc yakla\u015f\u0131mlar olu\u015fturuyoruz. Bunlar\u0131n yan\u0131 s\u0131ra, \u00f6zel sa\u011fl\u0131k inisiyatifleri kapsam\u0131nda yerelle\u015fme projelerini y\u00fcr\u00fct\u00fcyoruz. \u015eirket d\u0131\u015f\u0131nda olduk\u00e7a geni\u015f bir payda\u015f a\u011f\u0131m\u0131z var. Hem sekt\u00f6r\u00fcm\u00fcz hem de birimimiz a\u00e7\u0131s\u0131ndan en \u00f6nemli payda\u015flar\u0131m\u0131z tabii ki kamu kurumlar\u0131. Sosyal G\u00fcvenlik Kurumu, T\u00fcrkiye \u0130la\u00e7 ve T\u0131bbi Cihaz Kurumu, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131\u2019n\u0131n di\u011fer birimleri, Hazine ve Maliye Bakanl\u0131\u011f\u0131 en s\u0131k temasta oldu\u011fumuz kurumlar. Ayr\u0131ca sekt\u00f6rel dernekler, ticari birlikler, b\u00fcy\u00fckel\u00e7ilikler ve \u00fcniversiteler de birlikte \u00e7al\u0131\u015ft\u0131\u011f\u0131m\u0131z \u00f6nemli kurumlar aras\u0131nda yer al\u0131yor.<\/p>\n\n\n\n Bu alanda \u00e7al\u0131\u015fman\u0131n zorlu ve keyifli taraflar\u0131 neler?<\/strong><\/p>\n\n\n\n \u0130la\u00e7 sekt\u00f6r\u00fc, \u00e7al\u0131\u015fanlar\u0131n\u0131n e\u011fitim d\u00fczeyinin y\u00fcksek oldu\u011fu bir\u00e7ok farkl\u0131 alandan ve co\u011frafyadan ki\u015filerle \u00e7al\u0131\u015fman\u0131za olanak sa\u011flayan dinamik bir sekt\u00f6r. Ruhsatland\u0131rma ve pazar eri\u015fim hem global hem de T\u00fcrkiye organizasyonlar\u0131nda uzun y\u0131llard\u0131r keyif alarak \u00e7al\u0131\u015ft\u0131\u011f\u0131m bir alan. Ayn\u0131 anda birden \u00e7ok tedavi alan\u0131na destek verildi\u011finden kapsaml\u0131 bir geli\u015fim s\u00fcrecinin de i\u00e7inde oluyorsunuz. Her farkl\u0131 \u00fcr\u00fcn i\u00e7in yeni bir strateji geli\u015ftirme ve uygulama imk\u00e2n\u0131n\u0131z oluyor. Pazar eri\u015fim biriminin bir\u00e7ok kariyer f\u0131rsat\u0131 sundu\u011funu da d\u00fc\u015f\u00fcn\u00fcyorum; fakat i\u015fimizin do\u011fas\u0131 gere\u011fi bir stratejinin olu\u015fturulmas\u0131 ve hayata ge\u00e7mesi aras\u0131ndaki s\u00fcre \u00e7ok uzun olabiliyor ki bu da i\u015fimizin zorlay\u0131c\u0131 taraf\u0131 diyebilirim.<\/p>\n\n\n\n Bu alanda \u00e7al\u0131\u015fmak i\u00e7in ne gibi yetkinlikler gerekiyor? Biriminize yeni bir \u00e7al\u0131\u015fma arkada\u015f\u0131 dahil olacaksa adaydaki \u00f6ncelikli kriterleriniz neler olur?<\/strong><\/p>\n\n\n\n Bu alanda \u00e7al\u0131\u015fmay\u0131 d\u00fc\u015f\u00fcnen gen\u00e7ler geli\u015fim ve ara\u015ft\u0131rmaya a\u00e7\u0131k olmal\u0131lar. T\u00fcrkiye\u2019de ve d\u00fcnyada ruhsatland\u0131rma ve pazar eri\u015fim alan\u0131ndaki yenilikleri takip etmek, merakl\u0131 olmak \u00f6nemli. \u0130\u00e7 ve d\u0131\u015f bir\u00e7ok payda\u015fla \u00e7al\u0131\u015f\u0131ld\u0131\u011f\u0131 i\u00e7in ileti\u015fim yetene\u011fi bu birimde \u00e7al\u0131\u015fman\u0131n olmazsa olmaz\u0131. Ayn\u0131 zamanda analitik ve yenilik\u00e7i d\u00fc\u015f\u00fcnebilmek de \u00f6nemli bir \u00f6zellik. Ayr\u0131ca yabanc\u0131 dil seviyeleri de iyi olmal\u0131. Adaylar i\u00e7in \u00f6ncelikli kriterlerimiz bunlar.<\/p>\n\n\n\n Son olarak pazar eri\u015fimin gelece\u011fi hakk\u0131ndaki g\u00f6r\u00fc\u015flerinizi de alabilir miyiz?<\/strong><\/p>\n\n\n\n Pazar eri\u015fimin \u00f6nemini daha da art\u0131rarak gelecekte sekt\u00f6r\u00fcm\u00fcz\u00fcn kilit fonksiyonlar\u0131ndan biri olmaya devam edece\u011fini \u00f6ng\u00f6r\u00fcyorum. Yenilik\u00e7i tedavilerin do\u011fru hastalarla bulu\u015fturabilmesi bizim ve b\u00fct\u00fcn payda\u015flar\u0131m\u0131z\u0131n en b\u00fcy\u00fck arzusu. Bu ba\u011flamda pazar eri\u015fimin stratejik \u00f6neminin daha da artaca\u011f\u0131n\u0131, ayn\u0131 zamanda pazar eri\u015fim bak\u0131\u015f a\u00e7\u0131s\u0131n\u0131n sadece fonksiyonel de\u011fil, organizasyonel bir kabiliyet olma y\u00f6n\u00fcnde ilerleyece\u011fini de d\u00fc\u015f\u00fcn\u00fcyorum.<\/p>\n","protected":false},"excerpt":{"rendered":" AstraZeneca T\u00fcrkiye Ruhsatland\u0131rma ve Pazar Eri\u015fim Direkt\u00f6r\u00fc G\u00f6rkem Saka ile T\u00fcrkiye\u2019de ve d\u00fcnyada ila\u00e7lar\u0131n pazara eri\u015fim ve ruhsatland\u0131rma s\u00fcre\u00e7leri, pazar eri\u015fim fonksiyonun gelece\u011fi hakk\u0131nda bir sohbet ger\u00e7ekle\u015ftirdik.<\/p>\n","protected":false},"author":1,"featured_media":2651,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[66,131,97],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2650"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2650"}],"version-history":[{"count":5,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2650\/revisions"}],"predecessor-version":[{"id":2659,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/2650\/revisions\/2659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/2651"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2650"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2650"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"\"](\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2024\/01\/AZ_Gorkem_Saka_2023-1024x683.jpg\")
![\"\"](\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2024\/01\/AZ_Ruhsatlandirma_Pazar_Erisim_Ekip_2023-1024x683.jpg\")
<\/figure><\/div>\n\n\n